LSI's Medtech Startup Tracker is focused exclusively on covering the privately-held innovators changing the medical device landscape.
Instylla – liquid embolization using hydrogel technology
Instylla is developing liquid embolics for interventional oncology and peripheral hemostasis. In October 2020, Instylla announced that it had completed a Series B round of financing in which the company raised $25.4M. The company intends to use these funds to finance clinical trials, including a pivotal clinical trial in the US. Key strategics that offer liquid embolization products include Johnson & Johnson and Medtronic.
Whisper raises 35M in Series B round
The company commercializes the Whisper Hearing System, which is comprised of a pocket-sized “brain”, earpieces, and app. The Whisper Hearing System is differentiated from alternative hearing aid solutions by providing users with regular updates to the Whisper Brain, which processes and optimizes sound in real-time using the company’s proprietary Sound Separation Engine. Major competitors in the hearing aids market include Cochlear, Oticon, and ReSound.
Kegg – a wearable solution for female fertility tracking
Kegg commercializes a 2-in-1 fertility device that measures hormonal changes in a woman’s cervical fluid. The device is intended to help women monitor their optimal fertility window. Kegg is a novel solution for the fertility testing market, which has largely been dominated by ovulation prediction kits, home blood testing, and menstrual tracking. The company recently raised $1.5M in October 2016.
The company offers the FDA-cleared ExSpiron 1Xi, which uses bioelectrical impedance measurements to measure minute ventilation in non-intubated patients. Respiratory Motion’s technology is intended for use in the operating room, post-op-recovery, anesthesia, and intensive care settings. To-date, the company has raised $33.5M. Key players in the respiratory monitoring market include Cardinal Health, Draeger, and Masimo.
Elute is developing drug delivery technology for the prevention and treatment of infections
The company is developing a polymer-controlled drug delivery device that will help healthcare providers prevent and treat orthopedic and other surgical bone infections. The first product, EP Granules, provides a controlled release of antibiotics for 6 to 8 weeks. Strategics in the drug delivery and biomaterials markets include Bayer, Johnson & Johnson, and Pfizer.
WaveClear completes Series A fundraising round
The round, funded by Hunniwell Lake Ventures and Ben Franklin Technology Partners, was valued at $1.1M. WaveClear is developing an ultrasound-based therapy for the treatment of arterial occlusions. The key strategics in the cardiovascular therapies market include Abbott, Boston Scientific, and Medtronic.
Learn about the hottest venture funded startups developing innovative medical technologies using Life Science Intelligence’s Medtech Startup Tracker.